Mirtazapine for antipsychotic-induced acute akathisia: A systematic review and meta-analysis of randomized placebo-controlled trials

Samir Kumar Praharaj, Sreejayan Kongasseri, Rishikesh V. Behere, Podila Satya Venkata Narasimha Sharma

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

To conduct a systematic review and meta-analysis of randomized placebo-controlled trials of mirtazapine for the treatment of antipsychotic-induced acute akathisia (AIAA). Studies were identified using online searches of PUBMED/MEDLINE and Cochrane database (CENTRAL), along with websites recording trial information such as www.clinicaltrials.gov, www.controlled-trials.com, and www.clinicalstudyresults.org. The study eligibility criteria were randomized, double-blind clinical trials comparing mirtazapine with placebo for AIAA with standardized rating for akathisia as outcome measure. The methodological quality of included trials was assessed using the Jadad Scale. Separate meta-analyses were undertaken for each outcome (response rate and complete remission) and treatment effects were expressed as Mantel–Haenszel risk ratio (RR). Fixed-effect meta-analysis was performed as heterogeneity was not significant. Number need to treat (NNT) as a measure of relative treatment effectiveness was calculated. A systematic review of the literature revealed six studies that had assessed mirtazapine for the treatment of AIAA. Of these, two studies (n = 86) met the review inclusion criteria and were included in the final analysis. A meta-analysis was performed to see the effect size of response rate and complete remission. For response rate, RR was 6.67 [95% confidence interval (CI) 2.14–20.78], favoring mirtazapine compared with placebo, and the overall effect was significant (p = 0.001, NNT 4, 95% CI 2.6–8.6). For complete remission, RR was 6.20 (95% CI 1.74–22.08), favoring mirtazapine compared with placebo, and the overall effect was significant (p = 0.005, NNT 5, 95% CI 2.9–11.6). Although limited to only two studies and small sample, existing data support the efficacy of mirtazapine for the treatment of AIAA, with one in four patients showing partial response and one in five patients showing complete remission.

Original languageEnglish
Pages (from-to)307-313
Number of pages7
JournalTherapeutic Advances in Psychopharmacology
Volume5
Issue number5
DOIs
Publication statusPublished - 01-01-2015

Fingerprint

Psychomotor Agitation
Antipsychotic Agents
Meta-Analysis
Randomized Controlled Trials
Placebos
Confidence Intervals
Placebo Effect
Odds Ratio
MEDLINE
mirtazapine
Therapeutics
Outcome Assessment (Health Care)
Clinical Trials
Databases

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Psychology (miscellaneous)

Cite this

@article{c1cdc719a06d47fb9d43407147eac504,
title = "Mirtazapine for antipsychotic-induced acute akathisia: A systematic review and meta-analysis of randomized placebo-controlled trials",
abstract = "To conduct a systematic review and meta-analysis of randomized placebo-controlled trials of mirtazapine for the treatment of antipsychotic-induced acute akathisia (AIAA). Studies were identified using online searches of PUBMED/MEDLINE and Cochrane database (CENTRAL), along with websites recording trial information such as www.clinicaltrials.gov, www.controlled-trials.com, and www.clinicalstudyresults.org. The study eligibility criteria were randomized, double-blind clinical trials comparing mirtazapine with placebo for AIAA with standardized rating for akathisia as outcome measure. The methodological quality of included trials was assessed using the Jadad Scale. Separate meta-analyses were undertaken for each outcome (response rate and complete remission) and treatment effects were expressed as Mantel–Haenszel risk ratio (RR). Fixed-effect meta-analysis was performed as heterogeneity was not significant. Number need to treat (NNT) as a measure of relative treatment effectiveness was calculated. A systematic review of the literature revealed six studies that had assessed mirtazapine for the treatment of AIAA. Of these, two studies (n = 86) met the review inclusion criteria and were included in the final analysis. A meta-analysis was performed to see the effect size of response rate and complete remission. For response rate, RR was 6.67 [95{\%} confidence interval (CI) 2.14–20.78], favoring mirtazapine compared with placebo, and the overall effect was significant (p = 0.001, NNT 4, 95{\%} CI 2.6–8.6). For complete remission, RR was 6.20 (95{\%} CI 1.74–22.08), favoring mirtazapine compared with placebo, and the overall effect was significant (p = 0.005, NNT 5, 95{\%} CI 2.9–11.6). Although limited to only two studies and small sample, existing data support the efficacy of mirtazapine for the treatment of AIAA, with one in four patients showing partial response and one in five patients showing complete remission.",
author = "Praharaj, {Samir Kumar} and Sreejayan Kongasseri and Behere, {Rishikesh V.} and Sharma, {Podila Satya Venkata Narasimha}",
year = "2015",
month = "1",
day = "1",
doi = "10.1177/2045125315601343",
language = "English",
volume = "5",
pages = "307--313",
journal = "Therapeutic Advances in Psychopharmacology",
issn = "2045-1253",
publisher = "Sage Publications",
number = "5",

}

TY - JOUR

T1 - Mirtazapine for antipsychotic-induced acute akathisia

T2 - A systematic review and meta-analysis of randomized placebo-controlled trials

AU - Praharaj, Samir Kumar

AU - Kongasseri, Sreejayan

AU - Behere, Rishikesh V.

AU - Sharma, Podila Satya Venkata Narasimha

PY - 2015/1/1

Y1 - 2015/1/1

N2 - To conduct a systematic review and meta-analysis of randomized placebo-controlled trials of mirtazapine for the treatment of antipsychotic-induced acute akathisia (AIAA). Studies were identified using online searches of PUBMED/MEDLINE and Cochrane database (CENTRAL), along with websites recording trial information such as www.clinicaltrials.gov, www.controlled-trials.com, and www.clinicalstudyresults.org. The study eligibility criteria were randomized, double-blind clinical trials comparing mirtazapine with placebo for AIAA with standardized rating for akathisia as outcome measure. The methodological quality of included trials was assessed using the Jadad Scale. Separate meta-analyses were undertaken for each outcome (response rate and complete remission) and treatment effects were expressed as Mantel–Haenszel risk ratio (RR). Fixed-effect meta-analysis was performed as heterogeneity was not significant. Number need to treat (NNT) as a measure of relative treatment effectiveness was calculated. A systematic review of the literature revealed six studies that had assessed mirtazapine for the treatment of AIAA. Of these, two studies (n = 86) met the review inclusion criteria and were included in the final analysis. A meta-analysis was performed to see the effect size of response rate and complete remission. For response rate, RR was 6.67 [95% confidence interval (CI) 2.14–20.78], favoring mirtazapine compared with placebo, and the overall effect was significant (p = 0.001, NNT 4, 95% CI 2.6–8.6). For complete remission, RR was 6.20 (95% CI 1.74–22.08), favoring mirtazapine compared with placebo, and the overall effect was significant (p = 0.005, NNT 5, 95% CI 2.9–11.6). Although limited to only two studies and small sample, existing data support the efficacy of mirtazapine for the treatment of AIAA, with one in four patients showing partial response and one in five patients showing complete remission.

AB - To conduct a systematic review and meta-analysis of randomized placebo-controlled trials of mirtazapine for the treatment of antipsychotic-induced acute akathisia (AIAA). Studies were identified using online searches of PUBMED/MEDLINE and Cochrane database (CENTRAL), along with websites recording trial information such as www.clinicaltrials.gov, www.controlled-trials.com, and www.clinicalstudyresults.org. The study eligibility criteria were randomized, double-blind clinical trials comparing mirtazapine with placebo for AIAA with standardized rating for akathisia as outcome measure. The methodological quality of included trials was assessed using the Jadad Scale. Separate meta-analyses were undertaken for each outcome (response rate and complete remission) and treatment effects were expressed as Mantel–Haenszel risk ratio (RR). Fixed-effect meta-analysis was performed as heterogeneity was not significant. Number need to treat (NNT) as a measure of relative treatment effectiveness was calculated. A systematic review of the literature revealed six studies that had assessed mirtazapine for the treatment of AIAA. Of these, two studies (n = 86) met the review inclusion criteria and were included in the final analysis. A meta-analysis was performed to see the effect size of response rate and complete remission. For response rate, RR was 6.67 [95% confidence interval (CI) 2.14–20.78], favoring mirtazapine compared with placebo, and the overall effect was significant (p = 0.001, NNT 4, 95% CI 2.6–8.6). For complete remission, RR was 6.20 (95% CI 1.74–22.08), favoring mirtazapine compared with placebo, and the overall effect was significant (p = 0.005, NNT 5, 95% CI 2.9–11.6). Although limited to only two studies and small sample, existing data support the efficacy of mirtazapine for the treatment of AIAA, with one in four patients showing partial response and one in five patients showing complete remission.

UR - http://www.scopus.com/inward/record.url?scp=84998183236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998183236&partnerID=8YFLogxK

U2 - 10.1177/2045125315601343

DO - 10.1177/2045125315601343

M3 - Review article

AN - SCOPUS:84998183236

VL - 5

SP - 307

EP - 313

JO - Therapeutic Advances in Psychopharmacology

JF - Therapeutic Advances in Psychopharmacology

SN - 2045-1253

IS - 5

ER -